Bristol-Myers Squibb Inks $15 Billion Strategic Deal with Hengrui Pharma

Event Summary

On May 13, U.S. pharmaceutical giant Bristol-Myers Squibb entered into a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals. The deal could be worth more than $15 billion in total value.